ClinicalTrials.gg
CompletedNCT04908475Updated Apr 30, 2024Results posted

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

A Phase 4 interventional study of Risankizumab and Apremilast in Psoriasis, sponsored by AbbVie. Completed at 54 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-30.

Sponsored by AbbVie · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
7th of 30
352 · median 162
Started
2021
with 4 others
Phase 4
7 of 30
1 open now
Registered
26th of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 7th largest by enrollment, is one of 5 that started in 2021, is one of 7 in phase 4, and was the 26th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is compared to apremilast in adult participants with moderate plaque psoriasis. Adverse events and change in disease symptoms will be monitored.

Risankizumab (Skyrizi) and apremilast are approved drugs for the treatment of moderate to severe PsO. Approximately 330 participants with moderate plaque psoriasis (PsO) will be enrolled across approximately 55 sites globally.

The study has 2 periods : Period A from Baseline to Week 16, and Period B, from Week 16 to Week 52. In Period A, participants will be randomly placed into 2 groups to receive either subcutaneous risankizumab or oral apremilast for 16 weeks. In Period B, participants who received apremilast in Period A will again be randomly assigned to 1 of the 2 groups to receive either risankizumab or apremilast for 36 weeks. At weeks 28 and 40, participants considered non-responders to apremilast based on their psoriasis score will be offered to receive risankizumab.

There may be a higher burden for participants in this study compared to usual standard of care. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and questionnaires.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • Plaque Psoriasis
  • Risankizumab
  • ABBV-066
  • Skyrizi
  • Apremilast
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Candidates for systemic therapy with moderate chronic plaque psoriasis (PsO) (with or without psoriatic arthritis) at Screening and Baseline for at least 6 months prior to Baseline defined as:
  • Body Surface Area (BSA) >= 10% and \<= 15%; and
  • Psoriasis Area and Severity Index (PASI) >= 12; and
  • Static Physician Global Assessment (sPGA) = 3 (moderate) based on a 5-point scale (0 to 4).

Exclusion criteria

Exclusion Criteria:

  • Participant has any form of PsO other than chronic plaque PsO (e.g., pustular PsO, palmoplantar pustulosis, acrodermatitis of Hallopeau, erythrodermic, or guttate PsO).
  • History of current drug-induced PsO or a drug-induced exacerbation of pre-existing psoriasis.
  • History of active ongoing inflammatory skin diseases other than PsO and psoriatic arthritis that could interfere with the assessment of PsO (e.g., hyperkeratotic eczema).
  • Prior exposure to risankizumab or apremilast.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
352 participants (actual)

Study arms

  • Experimental
    Risankizumab

    Risankizumab 150 mg as a single subcutaneous (SC) injection at at Baseline (Day 1) and Week 4 (Period A) and at Weeks 16, 28, and 40 (Period B).

    Drug: Risankizumab

  • Experimental
    Apremilast

    Participants receive apremilast 30 mg orally twice daily (BID) in Period A and re-randomized to receive either risankizumab 150 mg as a single SC injection at Weeks 16, 20, 32 in Period B or apremilast 30 mg orally BID from Week 16 up to Week 52 in Period B. For those taking apremilast in Period B, non-responders at Week 28 and Week 40 will be offered to receive risankizumab as rescue medication.

    Drug: Risankizumab · Drug: Apremilast

Interventions

  • Subcutaneous injection

    Also known as: ABBV-066, Skyrizi

  • Oral Tablets

    Also known as: Otezla

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at Week 16 (ITT_A)

    The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.

    Time frame: Week 16

  2. Percentage of Participants Achieving Static Physician Global Assessment (sPGA) 0 or 1 With at Least 2-grade Improvement From Baseline in Intent to Treat Population at Week 16 (ITT_A)

    The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe).

    Time frame: Week 16

  3. Percentage of Participants Achieving PASI 90 in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR)

    The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Achieving PASI 75 (Defined as at Least 75% Improvement in PASI From Baseline) in Intent to Treat Population at Week 16 (ITT_A)

    The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.

    Time frame: Week 16

  2. Percentage of Participants Achieving PASI 75 in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR)

    The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.

    Time frame: Week 52

  3. Percentage of Participants Achieving Static Physician Global Assessment (sPGA) 0 or 1 With at Least 2-grade Improvement From Baseline in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR)

    The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe).

    Time frame: Week 52

07

Results

Posted Apr 30, 2024

Participant flow

A total of 352 participants were enrolled from 48 sites across 5 countries including Canada, Germany, Israel, Poland, and the United States.

Period A (Baseline to Week 16)
Participant flow — Period A (Baseline to Week 16)
MilestonePeriod A: APRPeriods A/B: RZB/RZBPeriod B: APR/APR, NRPeriod B: APR/RZB, NRPeriod B: APR/APR, RPeriod B: APR/RZB, R
Started2341180000
Completed2161180000
Not completed1800000
Withdrew: Lost to follow-up300000
Withdrew: Withdrawal by subject900000
Withdrew: Other, not specified600000
Period B (Week 16 to Week 52)
Participant flow — Period B (Week 16 to Week 52)
MilestonePeriod A: APRPeriods A/B: RZB/RZBPeriod B: APR/APR, NRPeriod B: APR/RZB, NRPeriod B: APR/APR, RPeriod B: APR/RZB, R
Started011878832220
Received ≥ 1 dose of study drug011675822220
Received rzb as rescue medication0047010
Completed06942571513
Not completed049362677
Withdrew: Lost to follow-up064600
Withdrew: Withdrawal by subject0513230
Withdrew: Other, not specified038191847

Outcome measures

PrimaryPercentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at Week 16 (ITT_A)

The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at Week 16 (ITT_A)
percentage of participantsPeriod A: APRPeriod A: RZB
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at Week 16 (ITT_A)5.1 (2.3 to 8.0)55.9 (47.0 to 64.9)
Statistical analysis
  • Period A: APR vs Period A: RZB · Cochran-Mantel-Haenszel · p = < 0.001 (Adjusted for strata (baseline body weight \[≤ 100 kg, \> 100 kg\] and prior exposure to any systemic and/or biologic treatment for psoriasis \[0, ≥ 1\]) for the comparison of 2 treatment groups.) · Adjusted difference: 50.7 · 95% CI 41.3 to 60.1
PrimaryPercentage of Participants Achieving Static Physician Global Assessment (sPGA) 0 or 1 With at Least 2-grade Improvement From Baseline in Intent to Treat Population at Week 16 (ITT_A)

The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) 0 or 1 With at Least 2-grade Improvement From Baseline in Intent to Treat Population at Week 16 (ITT_A)
percentage of participantsPeriod A: APRPeriod A: RZB
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) 0 or 1 With at Least 2-grade Improvement From Baseline in Intent to Treat Population at Week 16 (ITT_A)18.4 (13.4 to 23.3)75.4 (67.7 to 83.2)
Statistical analysis
  • Period A: APR vs Period A: RZB · Cochran-Mantel-Haenszel · p = < 0.001 (Adjusted for strata (baseline body weight \[≤ 100 kg, \> 100 kg\] and prior exposure to any systemic and/or biologic treatment for psoriasis \[0, ≥ 1\]) for the comparison of 2 treatment groups.) · Adjusted difference: 56.8 · 95% CI 47.7 to 66.0
PrimaryPercentage of Participants Achieving PASI 90 in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR)

The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 90 in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR)
percentage of participantsPeriod B: APR/APR, NRPeriod B: APR/RZB, NR
Percentage of Participants Achieving PASI 90 in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR)2.6 (0.0 to 6.1)72.3 (62.7 to 81.9)
Statistical analysis
  • Period B: APR/APR, NR vs Period B: APR/RZB, NR · Chi-squared · p = < 0.001 · Difference: 69.7 · 95% CI 59.5 to 80.0
SecondaryPercentage of Participants Achieving PASI 75 (Defined as at Least 75% Improvement in PASI From Baseline) in Intent to Treat Population at Week 16 (ITT_A)

The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 75 (Defined as at Least 75% Improvement in PASI From Baseline) in Intent to Treat Population at Week 16 (ITT_A)
percentage of participantsPeriod A: APRPeriod A: RZB
Percentage of Participants Achieving PASI 75 (Defined as at Least 75% Improvement in PASI From Baseline) in Intent to Treat Population at Week 16 (ITT_A)18.8 (13.8 to 23.8)84.7 (78.3 to 91.2)
Statistical analysis
  • Period A: APR vs Period A: RZB · Cochran-Mantel-Haenszel · p = < 0.001 (Adjusted for strata (baseline body weight \[≤ 100 kg, \> 100 kg\] and prior exposure to any systemic and/or biologic treatment for psoriasis \[0, ≥ 1\] for the comparison of 2 treatment groups.) · Adjusted difference: 65.9 · 95% CI 57.6 to 73.9
SecondaryPercentage of Participants Achieving PASI 75 in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR)

The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 75 in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR)
percentage of participantsPeriod B: APR/APR, NRPeriod B: APR/RZB, NR
Percentage of Participants Achieving PASI 75 in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR)11.5 (4.4 to 18.6)83.1 (75.1 to 91.2)
Statistical analysis
  • Period B: APR/APR, NR vs Period B: APR/RZB, NR · Chi-squared · p = < 0.001 · Difference: 71.6 · 95% CI 60.9 to 82.3
SecondaryPercentage of Participants Achieving Static Physician Global Assessment (sPGA) 0 or 1 With at Least 2-grade Improvement From Baseline in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR)

The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) 0 or 1 With at Least 2-grade Improvement From Baseline in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR)
percentage of participantsPeriod B: APR/APR, NRPeriod B: APR/RZB, NR
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) 0 or 1 With at Least 2-grade Improvement From Baseline in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR)7.7 (1.8 to 13.6)77.1 (68.1 to 86.1)
Statistical analysis
  • Period B: APR/APR, NR vs Period B: APR/RZB, NR · Chi-squared · p = < 0.001 · Difference: 69.4 · 95% CI 58.6 to 80.2

Adverse events

Collected over All Cause Mortality: From enrollment up to end of study, for an overall median of 419.5 days. Adverse Events: From first dose of study drug through approximately 20 weeks (140 days) after administration of the last dose of RZB (i.e., Week 40 for participants originally randomized to RZB and Week 44 for participants switched from APR to RZB) or approximately 4 weeks (28 days) after the last dose of APR (i.e., Week 56 for participants who remain on the APR arm after re-randomization).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period A: APR0/234 (0%)4/234 (1.7%)101/234 (43.2%)
Period A: RZB0/118 (0%)1/118 (0.8%)24/118 (20.3%)
Period B: RZB/RZB0/116 (0%)8/116 (6.9%)36/116 (31%)
Period B: APR/APR0/97 (0%)2/97 (2.1%)27/97 (27.8%)
Period B: APR/RZB0/102 (0%)3/102 (2.9%)31/102 (30.4%)
Period B: APR/APR/RZB0/48 (0%)0/48 (0%)15/48 (31.3%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventPeriod A: APRPeriod A: RZBPeriod B: RZB/RZBPeriod B: APR/APRPeriod B: APR/RZBPeriod B: APR/APR/RZB
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders0/2340/1182/1160/970/1020/48
CORONARY ARTERY DISEASECardiac disorders0/2340/1180/1161/970/1020/48
PROSTATE CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2340/1180/1161/970/1020/48
GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders0/2340/1180/1160/971/1020/48
HYPERSENSITIVITYImmune system disorders0/2340/1180/1160/971/1020/48
FALLInjury, poisoning and procedural complications0/2340/1180/1160/971/1020/48
LOWER LIMB FRACTUREInjury, poisoning and procedural complications0/2340/1180/1160/971/1020/48
URTICARIASkin and subcutaneous tissue disorders0/2340/1180/1160/971/1020/48
OBSTRUCTIVE PANCREATITISGastrointestinal disorders0/2340/1181/1160/970/1020/48
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders0/2340/1181/1160/970/1020/48
Most frequent other events
Most frequent other events
EventPeriod A: APRPeriod A: RZBPeriod B: RZB/RZBPeriod B: APR/APRPeriod B: APR/RZBPeriod B: APR/APR/RZB
DIARRHOEAGastrointestinal disorders47/2341/1180/1161/971/1020/48
NAUSEAGastrointestinal disorders41/2340/1182/1163/970/1020/48
COVID-19Infections and infestations16/23413/11819/11614/9712/1026/48
HEADACHENervous system disorders27/2343/1181/1164/975/1021/48
NASOPHARYNGITISInfections and infestations10/2344/11811/1168/9710/1025/48
HYPERTENSIONVascular disorders3/2342/1186/1160/971/1023/48
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations2/2343/1185/1163/976/1021/48

Baseline characteristics

Age, Continuous
Age, Continuous(years)Period A: APRPeriod A: RZBTotal
Mean46.2 ± 14.2745.5 ± 13.6346.0 ± 14.04
Sex: Female, Male
Sex: Female, Male(Participants)Period A: APRPeriod A: RZBTotal
Female7942121
Male15576231
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Period A: APRPeriod A: RZBTotal
Hispanic or Latino23730
Not Hispanic or Latino211111322
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Period A: APRPeriod A: RZBTotal
American Indian or Alaska Native101
Asian141226
Native Hawaiian or Other Pacific Islander123
Black or African American9514
White20998307
More than one race011
Unknown or Not Reported000
08

Study locations

54 sites
  • Total Skin and Beauty Dermatology Center /ID# 233793
    Birmingham, Alabama 35205, United States
  • Advanced Research Associates - Glendale /ID# 229266
    Glendale, Arizona 85308, United States
  • Alliance Dermatology and MOHs Center, PC /ID# 229224
    Phoenix, Arizona 85032, United States
  • UC Davis Health /ID# 229133
    Sacramento, California 95816-3300, United States
  • Florida Academic Centers Research and Education /ID# 229235
    Coral Gables, Florida 33134, United States
  • Olympian Clinical Research - Largo /ID# 233792
    Largo, Florida 33770, United States
  • Renstar Medical Research /ID# 228946
    Ocala, Florida 34470, United States
  • ForCare Clinical Research /ID# 229135
    Tampa, Florida 33613-1244, United States
  • Arlington Dermatology /ID# 228945
    Rolling Meadows, Illinois 60008, United States
  • Dawes Fretzin, LLC /ID# 229010
    Indianapolis, Indiana 46256, United States
  • Epiphany Dermatology of Kansas LLC /ID# 229221
    Overland Park, Kansas 66210, United States
  • DermAssociates, LLC /ID# 229016
    Rockville, Maryland 20850, United States
  • Michigan Center for Research Company /ID# 229136
    Clarkston, Michigan 48346, United States
  • Henry Ford Medical Center /ID# 229215
    Detroit, Michigan 48202-3046, United States
  • MediSearch Clinical Trials /ID# 229269
    Saint Joseph, Missouri 64506, United States
  • Physician Research Collaboration, LLC /ID# 229225
    Lincoln, Nebraska 68516, United States
  • Advanced Dermatology of the Midlands /ID# 229009
    Omaha, Nebraska 68144-1105, United States
  • Psoriasis Treatment Center of Central New Jersey /ID# 228943
    East Windsor, New Jersey 08520, United States
  • University Hospitals Case Medical Center /ID# 229240
    Cleveland, Ohio 44106, United States
  • Wright State Physicians - Fairborn /ID# 230051
    Fairborn, Ohio 45324-2640, United States
  • Oregon Dermatology and Research Center /ID# 233462
    Portland, Oregon 97210, United States
  • Arlington Research Center, Inc /ID# 229264
    Arlington, Texas 76011, United States
  • Bellaire Dermatology Associates /ID# 230118
    Bellaire, Texas 77401, United States
  • Center for Clinical Studies - Houston (Binz) /ID# 229263
    Houston, Texas 77004-8097, United States
  • Center for Clinical Studies - Houston (Binz) /ID# 229272
    Houston, Texas 77004-8097, United States
  • Premier Clinical Research /ID# 229220
    Spokane, Washington 99202, United States
  • Beacon Dermatology Inc /ID# 230121
    Calgary, Alberta T3E 0B2, Canada
  • Dr. Chih-ho Hong Medical Inc. /ID# 230337
    Surrey, British Columbia V3R 6A7, Canada
  • Enverus Medical Research /ID# 230480
    Surrey, British Columbia V3V 0C6, Canada
  • Karma Clinical Trials /ID# 230339
    St. John's, Newfoundland and Labrador A1A 4Y3, Canada
  • Dermatrials Research /ID# 230119
    Hamilton, Ontario L8N 1Y2, Canada
  • Dr. S.K. Siddha Medicine Professional Corporation /ID# 230416
    Newmarket, Ontario L3Y 5G8, Canada
  • K. Papp Clinical Research /ID# 230336
    Waterloo, Ontario N2J 1C4, Canada
  • Innovaderm Research Inc. /ID# 230334
    Montréal, Quebec H2X 2V1, Canada
  • Centre de Recherche dermatologique du Quebec Metropolitain /ID# 230478
    Québec, Quebec G1V 4X7, Canada
  • Universitaetsklinikum Erlangen /ID# 229433
    Erlangen, Bayern 91054, Germany
  • Universitaetsklinikum Frankfurt /ID# 229431
    Frankfurt am Main, Hessen 60590, Germany
  • Universitaetsklinikum Muenster /ID# 229432
    Munster, Niedersachsen 48149, Germany
  • DermaKiel Allergie und Haut Centrum /ID# 229630
    Kiel, Schleswig-Holstein 24148, Germany
  • Fachklinik Bad Bentheim /ID# 231504
    Bad Bentheim, 48455, Germany
  • Hautarztpraxis Dr. Niesmann und Dr. Othlinghaus /ID# 230245
    Bochum, 44793, Germany
  • SRH Wald-Klinikum Gera /ID# 229445
    Gera, 07548, Germany
  • MENSINGDERMA research GmbH /ID# 229435
    Hamburg, 22391, Germany
  • Dermatologische Gemeinschaftspraxis Mahlow /ID# 229434
    Mahlow, 15831, Germany
  • Rambam Health Care Campus /ID# 229620
    Haifa, H_efa 3109601, Israel
  • Rabin Medical Center /ID# 229074
    Haifa, H_efa 4941492, Israel
  • HaEmek Medical Center /ID# 231901
    Afula, HaDarom 1834111, Israel
  • The Chaim Sheba Medical Center /ID# 229075
    Ramat Gan, Tel-Aviv 5265601, Israel
  • Dermed Centrum Medyczne Sp. z o.o /ID# 229051
    Lodz, Lodzkie 90-265, Poland
  • High-Med Przychodnia Specjalistyczna /ID# 229023
    Warszawa, Mazowieckie 01-817, Poland
  • Royalderm Agnieszka Nawrocka /ID# 228973
    Warszawa, Mazowieckie 02-962, Poland
  • Uniwersytecki Szpital Kliniczny im. F. Chopina w Rzeszowie /ID# 229022
    Rzeszow, Podkarpackie 35-055, Poland
  • Centrum Badan Klinicznych PI-House sp. z o.o. /ID# 229053
    Gdansk, Pomorskie 80-546, Poland
  • Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 228971
    Elblag, Warminsko-mazurskie 82-300, Poland
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Apr 2023, 22 months.

Results were first posted in Apr 2024, 1 year after primary completion.

Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 22 months is close to that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2021
First posted
Jun 1, 2021
StartActual
Jun 9, 2021
Primary completionActual
Apr 20, 2023
CompletionActual
Apr 20, 2023
Results first posted
Apr 30, 2024
Last update
Apr 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04908475
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 1, 2021
Start date
Jun 9, 2021
Primary completion
Apr 20, 2023
Completion
Apr 20, 2023
Results posted
Apr 30, 2024
Last update
Apr 30, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion